Microba Life Sciences (ASX:MAP) has announced that stage one activity screening for its autoimmune disease program has been completed on schedule with partner Ginkgo Bioworks.
Microba completes stage one screening for its autoimmune disease program
November 29, 2023 Australian Biotech
Latest Video
New Stories
-
‘Game-changer’ clinical trial launches for Australia’s second-deadliest cancer
April 29, 2025 - - Latest News -
These system-shifting therapies come along every few years, but this is different
April 29, 2025 - - Latest News -
Culture review delivers a scathing assessment of New Zealand's Pharmac
April 29, 2025 - - Latest News -
Pfizer-commissioned survey reveals rising GP concerns over medical misinformation
April 29, 2025 - - Latest News -
New survey confirms significant interest in accessing weight loss therapies
April 28, 2025 - - Latest News -
Medicines Australia announces appointment of communications director
April 28, 2025 - - Latest News -
Recce Pharmaceuticals enters research and development agreement with US defence
April 28, 2025 - - Australian Biotech